BR112022022418A2 - Anticorpos de alvejamento de clec12a e uso dos mesmos - Google Patents

Anticorpos de alvejamento de clec12a e uso dos mesmos

Info

Publication number
BR112022022418A2
BR112022022418A2 BR112022022418A BR112022022418A BR112022022418A2 BR 112022022418 A2 BR112022022418 A2 BR 112022022418A2 BR 112022022418 A BR112022022418 A BR 112022022418A BR 112022022418 A BR112022022418 A BR 112022022418A BR 112022022418 A2 BR112022022418 A2 BR 112022022418A2
Authority
BR
Brazil
Prior art keywords
clec12a
proteins
targeting antibodies
pharmaceutical compositions
paired
Prior art date
Application number
BR112022022418A
Other languages
English (en)
Portuguese (pt)
Inventor
Baruah Hemanta
P Chang Gregory
F Cheung Ann
Grinberg Asya
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of BR112022022418A2 publication Critical patent/BR112022022418A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112022022418A 2020-05-06 2021-05-05 Anticorpos de alvejamento de clec12a e uso dos mesmos BR112022022418A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063020806P 2020-05-06 2020-05-06
PCT/US2021/030773 WO2021226163A2 (en) 2020-05-06 2021-05-05 Antibodies targeting clec12a and use thereof

Publications (1)

Publication Number Publication Date
BR112022022418A2 true BR112022022418A2 (pt) 2022-12-13

Family

ID=78468386

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022022418A BR112022022418A2 (pt) 2020-05-06 2021-05-05 Anticorpos de alvejamento de clec12a e uso dos mesmos

Country Status (11)

Country Link
US (1) US20230220084A1 (https=)
EP (1) EP4146704A4 (https=)
JP (1) JP2023524997A (https=)
KR (1) KR20230008157A (https=)
CN (1) CN115697402A (https=)
AU (1) AU2021267023A1 (https=)
BR (1) BR112022022418A2 (https=)
CA (1) CA3177818A1 (https=)
IL (1) IL297950A (https=)
MX (1) MX2022013882A (https=)
WO (1) WO2021226163A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202091887A1 (ru) 2018-02-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры
DK3749346T3 (da) 2018-02-08 2024-09-09 Dragonfly Therapeutics Inc Antistof variable domænekombinationer rettet mod nkg2d-receptoren
WO2020033630A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
US12378318B2 (en) 2018-08-08 2025-08-05 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and a tumor-associated antigen
EP4291233A4 (en) * 2021-02-10 2025-05-21 Wugen, Inc. POLYPEPTIDES AND THEIR USE IN THE TREATMENT OF DISEASES
JP2024508894A (ja) 2021-03-03 2024-02-28 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
GB202214132D0 (en) * 2022-09-27 2022-11-09 Coding Bio Ltd CLL1 binding molecules

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009523460A (ja) * 2006-01-24 2009-06-25 ドマンティス リミテッド Ｉｌ−４および／またはｉｌ−１３に結合するリガンド
WO2008127735A1 (en) * 2007-04-13 2008-10-23 Stemline Therapeutics, Inc. Il3ralpha antibody conjugates and uses thereof
US9163090B2 (en) * 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
EP3470431A1 (en) * 2012-09-27 2019-04-17 Merus N.V. Bispecific igg antibodies as t cell engagers
EP3310378B1 (en) * 2015-06-16 2024-01-24 F. Hoffmann-La Roche AG Anti-cll-1 antibodies and methods of use
WO2017011342A1 (en) * 2015-07-10 2017-01-19 Abbvie Inc. Igm-or-ige-modified binding proteins and uses thereof
AU2017330346C1 (en) * 2016-09-21 2025-03-06 Nextcure, Inc. Antibodies for Siglec-15 and methods of use thereof
SG11202002298PA (en) * 2017-09-14 2020-04-29 Dragonfly Therapeutics Inc Proteins binding nkg2d, cd16, and c-type lectin-like molecule-1 (cll-1)
US12097219B2 (en) * 2018-09-10 2024-09-24 Legend Biotech Ireland Limited Single-domain antibodies against CLL1 and constructs thereof

Also Published As

Publication number Publication date
US20230220084A1 (en) 2023-07-13
EP4146704A4 (en) 2024-08-28
CN115697402A (zh) 2023-02-03
KR20230008157A (ko) 2023-01-13
AU2021267023A1 (en) 2022-12-01
MX2022013882A (es) 2022-11-30
WO2021226163A2 (en) 2021-11-11
WO2021226163A3 (en) 2021-12-16
EP4146704A2 (en) 2023-03-15
JP2023524997A (ja) 2023-06-14
IL297950A (en) 2023-01-01
CA3177818A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
BR112022022418A2 (pt) Anticorpos de alvejamento de clec12a e uso dos mesmos
BR112023002150A2 (pt) Anticorpos direcionando egfr e uso dos mesmos
MX2020008336A (es) Dominios variables de anticuerpos que se dirigen al receptor nkg2d.
BR112022006817A2 (pt) Anticorpos direcionados a flt3 e uso dos mesmos
EA202091976A1 (ru) Вариабельные домены антител, нацеленные на cd33, и их применение
EA202091888A1 (ru) Вариабельные домены антител, нацеленные на рецептор nkg2d
DOP2019000280A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso
BR112022026236A2 (pt) Terapia de combinação de imuno-oncologia com conjugados de il-2 e anticorpos anti-egfr
BR112022002442A2 (pt) Terapias de imuno-oncologia com conjugados de il-2
MX2024003913A (es) Anticuerpos dirigidos al receptor del factor activador de celulas b (baff-r) y uso de los mismos.
DOP2024000207A (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
BR112016030686A2 (pt) anticorpos anti tau humanizados
UY39191A (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
BR112021008060A2 (pt) Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento
BR112022004972A2 (pt) Anticorpos, ácidos nucleicos isolados, células hospedeiras isoladas, métodos de produção de um anticorpo, de produção de um anticorpo biespecífico e de tratamento de um indivíduo, anticorpos biespecíficos, composição farmacêutica, anticorpo, anticorpo biespecífico ou composição farmacêutica, combinação de um anticorpo, uso do anticorpo, uso de uma combinação do anticorpo e métodos para reduzir a inflamação e para melhorar a descamação e/ou de erupção cutânea e combinação para uso
ECSP21044421A (es) Anticuerpos anti-pmel17 y conjugados de los mismos
MX2021003673A (es) Anticuerpos anti-vsig4 humano y usos de los mismos.
BR112022011570A2 (pt) Anticorpos anti-mertk e métodos de uso dos mesmos
EA202092136A1 (ru) Способы лечения рака с помощью комбинации антитела к pd-1 и конъюгата антитела к тканевому фактору и лекарственного средства
EA202190734A1 (ru) Способы лечения рака с помощью комбинации антитела против vegf и конъюгата антитело против тканевого фактора-лекарственное средство
BR112021016596A2 (pt) Anticorpo anti-pd-l1 e uso do mesmo
BR112023024772A2 (pt) Anticorpos anti-nkg2a e composições
EA202192008A1 (ru) Lilrb3-связывающие молекулы и варианты их применения
MX2021006396A (es) Tratamiento topico de la diarrea, colitis o enterocolitis inducida por inhibidores de puntos de control inmunologico, utilizando anticuerpos y fragmentos de los mismos.
BR112019011370A2 (pt) terapia de combinação

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.